In:
European Archives of Oto-Rhino-Laryngology, Springer Science and Business Media LLC, Vol. 281, No. 7 ( 2024-07), p. 3671-3678
Kurzfassung:
Although COVID-19 anosmia is often transient, patients with persistent olfactory dysfunction (pOD) can experience refractory parosmia and diminished smell. This study evaluated four putative therapies for parosmia in patients with chronic COVID-19 olfactory impairment. Methods After screening nasal endoscopy, 85 patients (49 female, 58%) with pOD and treatment-refractory parosmia were randomized to: (1) ultramicronized palmitoylethanolamide and luteolin + olfactory training (OT) ( umPEALUT group , n = 17), (2) alpha-lipoic acid + OT ( ALA group , n = 21), (3) umPEALUT + ALA + OT ( combination group , n = 28), or 4) olfactory training (OT) alone ( control group , n = 23). Olfactory function was assessed at baseline (T 0 ) and 6 months (T 1 ) using a parosmia questionnaire and Sniffin’ Sticks test of odor threshold, detection, and identification (TDI). Analyses included one-way ANOVA for numeric data and Chi-Square analyses for nominal data on parosmia. Results The umPEALUT group had the largest improvement in TDI scores (21.8 ± 9.4 to 29.7 ± 7.5) followed by the combination group (19.6 ± 6.29 to 27.5 ± 2.7), both p 〈 0.01. The control and ALA groups had no significant change. Patients in the combination and umPEALUT groups had significantly improved TDI scores compared to ALA and control groups (p 〈 0.001). Rates of parosmia resolution after 6 months were reported at 96% for combination, 65% for control, 53% for umPEALUT and 29% for ALA (p 〈 0.001). All treatment regimens were well-tolerated. Conclusions umPEALUT and OT, with or without ALA, was associated with improvement in TDI scores and parosmia, whereas OT alone or OT with ALA were associated with little benefit.
Materialart:
Online-Ressource
ISSN:
0937-4477
,
1434-4726
DOI:
10.1007/s00405-024-08548-6
Sprache:
Englisch
Verlag:
Springer Science and Business Media LLC
Publikationsdatum:
2024
ZDB Id:
1459042-6
ZDB Id:
2141531-6
Permalink